Chloroquine Related to Malaria and its Promising Applications for Covid-19 Treatment
Keywords:
Cloroquine, COVID-19, QT intervalAbstract
Objective: this article described the use of chloroquine as an antimalarial agent with potential antiviral indications for COVID-19 infections. Methods: this article consisted of online searches and gray literature whose database included PUBMED Central, BVS/BIREME, Web of Science, Science Direct, Higher Level Personnel Improvement Coordinator (CAPES), Periodic Door (Portal de Periódicos da CAPES, The Cochrane Library, and PROSPERO). Results: chloroquine and hydroxychloroquine have shown appropriate clinical reports when associated with the antibiotic Azithromycin. It has been authorized for the clinical treatment of severe acute forms of COVID infections by countries such as Brazil and the USA. Conclusions: Chloroquine seems to have potential antiviral properties that may be useful in the treatment of these severe acute forms of COVID-19 associated with Azithromycin. Nevertheless, its indication must include ECG monitoring due to the risk of prolongation of QT interval, leading to sudden cardiac death.
Downloads
References
Fern, Ken (2010–2020). "Cinchona officinalis – L." Plans for a Future. Archived from the original on 25 August 2017. Retrieved 2 February 2020.
Krafts K, Hempelmann E, Skórska-Stania A (July 2012). "From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy". Parasitology Research. 111 (1): 1–6.
Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am. 1994;20(1): 243-63. Review.
Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol. 1997;36(7):799-805. Comment in: Br J Rheumatol. 1998;37(5):580.
Peters, W. -Chemotherapy and drug resistance in malaria. Ipswich, Academic Press, 1970. 876 p.
Smith T, Bushek J, Prosser T. COVID-19 Drug therapy – Potential Options. Elsevier, March 26, 2020.
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (November 2003). "Effects of chloroquine on viral infections: an old drug against today's diseases?". The Lancet. Infectious Diseases. 3 (11): 722–7.
Al-Bari MA (February 2017). "Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases". Pharmacology Research & Perspectives. 5 (1): e00293. doi:10.1002/prp2.293. PMC 5461643. PMID 28596841.
Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV (November 2002). "Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus". Journal of Virology. 76 (22): 11440–6. doi:10.1128/JVI.76.22.11440-11446.2002. PMC 136743. PMID 12388705.
Haeusler, IL; Chan, XHS; Guérin, XHS; Guérin, PJ; White, NJ. The arrhythmogenic cardiotoxicity of the Quinoline and structurally related antimalarial drugs: A systematic review. BMC Med, 16(1), 200. 2018.
Rey, LD. ECT QT interval prolongation in reumathic patients using antimalarial drugs. Rev. Bras. REumatol. (on line). 2003. Vol.43, n.5, pp.275-278. ISSN 0482-5004. https://doi.org/10.1590/S0482-5004200300500003.
January C., Riddle J. (1989) Early after depolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 64: 977–990.
